Methyl 4-(isopropylamino)butanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 4-(isopropylamino)butanoate
• 英文别名: methyl 4-(propan-2-ylamino)butanoate
• 化学式: C₈H₁₇NO₂
• mdl: MFCD12166182
• 分子量: 159.23
• InChiKey: RSJKCQHGLDSNIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] LIPID NANOPARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE NANOPARTICULES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018081480A1

  公开（公告）日：2018-05-03

  Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

  提供了改进的脂质纳米粒子配方。还提供了利用这些脂质纳米粒子传递治疗剂的方法以及它们的制备方法。
• [EN] LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS<br/>[FR] LIPIDES ET FORMULATIONS DE NANOPARTICULES DE LIPIDES POUR LA LIBÉRATION D'ACIDES NUCLÉIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2017117528A1

  公开（公告）日：2017-07-06

  Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或（II）的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中R、R1、R2、L、X、L、G1、G2、Z、a1、a2和n分别如本文所定义的用于结构（I）和（II）。还提供了将这些化合物用作脂质纳米粒子配方的组分以传递治疗剂、包含这些化合物的组合物以及其使用和制备方法。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• Polyene macrolide derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10246478B2

  公开（公告）日：2019-04-02

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。